Introduction:
Simtra BioPharma Solutions, recently acquired by Advent International and Warburg Pincus, is expanding its sterile fill/finish manufacturing campus in Bloomington, Indiana.
Features:
The expansion involves the construction of a new 150,000 square foot building.
This building will accommodate two high-speed automated isolator syringe fill lines and a new high-speed isolator vial line with three 30 square meter lyophilizers.
Each process suite in the new building will feature dedicated formulation/compounding rooms.
The expansion also includes a dedicated clinical line to support early-stage projects, utilizing existing facility infrastructure.
The expansion is projected to create hundreds of new jobs in Bloomington.
The clinical line is expected to be operational by summer 2025.
Construction of the new building will commence in June 2024 and is anticipated to be completed in two years, with GMP readiness expected by late 2026.
Specifications:
Name Simtra BioPharma
Type Expansion
Year 2026
